Asset Details
Do you wish to reserve the book?
Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir
Do you wish to request the book?
Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir
2010
Overview
Purpose This study aimed to investigate the effect of antivirals ritonavir and lopinavir/ritonavir on the pharmacokinetics and pharmacodynamics of oral oxycodone, a widely used opioid receptor agonist used in the treatment of moderate to severe pain. Methods A randomized crossover study design with three phases at intervals of 4 weeks was conducted in 12 healthy volunteers. Ritonavir 300 mg, lopinavir/ritonavir 400/100 mg, or placebo b.i.d. for 4 days was given to the subjects. On day 3, 10 mg oxycodone hydrochloride was administered orally. Plasma concentrations of oxycodone, noroxycodone, oxymorphone, and noroxymorphone were determined for 48 h. Pharmacokinetic parameters were calculated with standard noncompartmental methods. Behavioral effects and experimental cold pain analgesia were assessed for 12 h. ANOVA for repeated measures was used for statistical analysis. Results Ritonavir and lopinavir/ritonavir increased the area under the plasma concentration-time curve of oral oxycodone by 3.0-fold (range 1.9- to 4.3-fold; P <0.001) and 2.6-fold (range 1.9- to 3.3-fold; P <0.001). The mean (± SD) elimination half-life increased after ritonavir and lopinavir/ritonavir from 3.6 ± 0.6 to 5.6 ± 0.9 h (P <0.001) and 5.7 ± 0.9 h (P <0.001), respectively. Both ritonavir (P <0.001) and lopinavir/ritonavir (P <0.05) increased the self-reported drug effect of oxycodone. Conclusions Ritonavir and lopinavir/ritonavir greatly increase the plasma concentrations of oral oxycodone in healthy volunteers and enhance its effect. When oxycodone is used clinically in patients during ritonavir and lopinavir/ritonavir treatment, reductions in oxycodone dose may be needed to avoid opioid-related adverse effects.
Publisher
Berlin/Heidelberg : Springer-Verlag,Springer-Verlag,Springer,Springer Nature B.V,Springer Verlag
Subject
/ Adult
/ Analgesics, Opioid - administration & dosage
/ Analgesics, Opioid - pharmacokinetics
/ Analgesics, Opioid - pharmacology
/ Biological and medical sciences
/ Biomedical and Life Sciences
/ blood
/ Drug Administration Schedule
/ Female
/ Finland
/ HIV Infections - complications
/ HIV Infections - drug therapy
/ HIV Protease Inhibitors - administration & dosage
/ HIV Protease Inhibitors - adverse effects
/ HIV Protease Inhibitors - pharmacology
/ Humans
/ Kinetics
/ Male
/ Oxycodone - administration & dosage
/ Oxycodone - pharmacokinetics
/ Pain
/ Pharmacology. Drug treatments
/ Pyrimidinones - administration & dosage
/ Pyrimidinones - adverse effects
/ Pyrimidinones - pharmacology
